ELAN, US28414H1032

Elanco schedules November 6 results for Elanco Animal Health stock

Published on 10/27/2026 at 20:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Revenue rose 10.20 percent in the second quarter. Elanco Animal Health stock costs EUR 20.41 on October 27, 2026, minus 0.10 percent versus Xetra close.

Reporting date November 6, 2026

  • Elanco scheduled its third-quarter earnings call for November 6, 2026.
  • Second-quarter revenue rose 10.20 percent to USD 1.368 billion.
  • Elanco Animal Health stock costs EUR 20.41 at Lang & Schwarz on October 27, 2026 at 8:17 p.m. CET, minus 0.10 percent versus the Xetra close of October 27, 2026 at EUR 20.43.
  • Elanco's market capitalization was USD 11.3 billion as of October 27, 2026.
ELAN, US28414H1032, Illustration mit AI erstellt.

Elanco Animal Health (US28414H1032) has set November 6, 2026 for its third-quarter earnings call, according to the company's Investor Relations page. At Lang & Schwarz, the stock was trading at EUR 20.41 on October 27, 2026 at 8:17 p.m. CET, minus 0.10 percent versus the Xetra close of October 27, 2026 at EUR 20.43.

November 6 is the next date

The November event gives investors the next scheduled checkpoint after Elanco's second-quarter performance. The company lists the event as its third-quarter 2026 earnings call, starting at 8:00 a.m. EST on November 6, 2026, on its investor calendar.

Second-quarter growth reached 10.20 percent

Elanco reported USD 1.368 billion in revenue for the second quarter ended June 30, 2026, an increase of 10.20 percent from the year-earlier period, according to the Benzinga transcript. Adjusted gross margin reached 58.10 percent in the quarter, up 80 basis points from the same period a year earlier.

NYSE valuation sets the frame

On the NYSE, Elanco stock last traded at USD 22.65 on October 27, 2026 at 3:20 p.m. ET, down 1.35 percent from the prior close. Its market capitalization was USD 11.3 billion, while the 52-week range stood at USD 19.40 to USD 27.98 on the same date.

The second-quarter update also included full-year 2026 guidance of USD 5.09 billion to USD 5.14 billion in revenue and adjusted earnings per share of USD 1.10 to USD 1.16. The scheduled November 6 call will provide the next company update on those ranges and on third-quarter execution.

Price stays close to the Xetra close

The small euro-market gap keeps the German trading perspective nearly unchanged after the Xetra session. The Lang & Schwarz price was EUR 0.02 below the Xetra close, equivalent to minus 0.10 percent after the Xetra close.

Elanco develops animal-health products for companion animals and livestock. Its business spans vaccines, parasiticides, antibiotics and nutritional products, giving the November reporting date relevance for both pet-health demand and farm-animal sales.

The further course of trading is shown by the continuously updated real-time quote of Elanco Animal Health stock.

Elanco Animal Health at a glance

  • Company: Elanco Animal Health Incorporated
  • ISIN: US28414H1032
  • Ticker: ELAN
  • Primary exchange: NYSE
  • Price Lang & Schwarz (as of October 27, 2026 at 8:17 p.m. CET): EUR 20.41
  • Change versus Xetra close: minus 0.10 percent
  • Xetra close (October 27, 2026): EUR 20.43
  • Market capitalization: USD 11.3 billion (as of October 27, 2026)
  • 52-week range: USD 19.40-27.98 (as of October 27, 2026)
  • Sector / Industry: Healthcare / Drug Manufacturers - Specialty and Generic

Market context: Market report S&P 500.

More news and analyses on Elanco Animal Health stock

Disclaimer...
en | US28414H1032 | ELAN | boerse | 70423002 |